Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial

Abstract Background The standard treatment for localized/locally advanced gastroesophageal adenocarcinoma (GEA) is radical surgery and peri-operative FLOT treatment (5-fluorouracil plus leucovorin, oxaliplatin, and docetaxel), but around half patients still experience disease relapse. In gastrointes...

Full description

Saved in:
Bibliographic Details
Main Authors: Vincenzo Nasca, Francesca Bergamo, Luisa Foltran, Lorenzo Antonuzzo, Katia Bencardino, Emanuela Dell’Aquila, Salvatore Corallo, Andrea Spallanzani, Oronzo Brunetti, Daniele Spada, Stefano Tamberi, Chiara Alessandra Cella, Antonio Avallone, Lorenzo Fornaro, Samantha Di Donato, Antonia Strippoli, Alberto Puccini, Emiliano Tamburini, Federica Palermo, Federica Morano, Filippo Pietrantonio, Alessandra Raimondi
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Cancer
Subjects:
Gastric cancer
Esophageal cancer
HER2
Liquid biopsy
Trastuzumab-deruxtecan
Online Access:https://doi.org/10.1186/s12885-025-14063-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14063-6

Similar Items